FDA Review of Varenicline and Risk of Cardiovascular Adverse Events

Published Online: Wednesday, December 19, 2012
Follow Pharmacy_Times:
This podcast, from the Centers for Disease Control and Prevention, discusses a drug safety communication released by the FDA on December 12, 2012, regarding the risk of cardiovascular adverse events associated with the smoking-cessation drug varenicline (Chantix).
 
To download the podcast, click here.
Related Articles
Two groups of students from MCPHS University were named winners of the People’s Choice Poster Competition at the 10th Annual New England Pharmacists Convention.
Even though smoking can exacerbate respiratory conditions and limit the efficacy of their treatment, patients often purchase cigarettes while filling prescriptions for asthma or antihypertensive drugs at pharmacies.
Patients with moderate-to-severe psoriasis are more likely to have uncontrolled hypertension.
The disease burden of smoking remains immense despite widespread tobacco cessation efforts.
Latest Issues
$auto_registration$